| scholarly article | Q13442814 |
| P50 | author | Jorge E. Osorio | Q28743695 |
| P2093 | author name string | Charalambos D Partidos | |
| Joseph D Santangelo | |||
| Shi-Hsia Hwa | |||
| Joseph N Brewoo | |||
| Yock Ann Lee | |||
| P2860 | cites work | A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice | Q84195454 |
| Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71 | Q95821973 | ||
| Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. | Q39835244 | ||
| Differences in perception of dysentery and enteric fever and willingness to receive vaccines among rural residents in China | Q40498833 | ||
| Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease | Q41988715 | ||
| A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine | Q42694361 | ||
| Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. | Q43523822 | ||
| Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. | Q43914758 | ||
| Combined peptides of human enterovirus 71 protect against virus infection in mice | Q43934303 | ||
| Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. | Q43981254 | ||
| Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement | Q45361800 | ||
| Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | Q45396589 | ||
| Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice | Q46354156 | ||
| Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. | Q46550828 | ||
| Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. | Q47736273 | ||
| Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease | Q48405572 | ||
| Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005 | Q80290931 | ||
| Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey | Q81299406 | ||
| DNA vaccine constructs against enterovirus 71 elicit immune response in mice | Q21245503 | ||
| Production of EV71 vaccine candidates | Q26866091 | ||
| Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak | Q27487876 | ||
| The Enterovirus 71 A-particle Forms a Gateway to Allow Genome Release: A CryoEM Study of Picornavirus Uncoating | Q27677204 | ||
| Scavenger receptor B2 is a cellular receptor for enterovirus 71 | Q28249350 | ||
| Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes | Q33255718 | ||
| Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998 | Q33824871 | ||
| Neurologic complications in children with enterovirus 71 infection | Q33875092 | ||
| Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. | Q33908518 | ||
| Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice | Q33958090 | ||
| Typing of human enteroviruses by partial sequencing of VP1. | Q33960048 | ||
| Forecasting the economic value of an Enterovirus 71 (EV71) vaccine | Q34338981 | ||
| Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 | ||
| Challenges to licensure of enterovirus 71 vaccines | Q34406820 | ||
| Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice | Q34430681 | ||
| Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development | Q34607995 | ||
| Non-clinical vaccine safety assessment | Q34612424 | ||
| Adaptation of enterovirus 71 to adult interferon deficient mice | Q34635242 | ||
| An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 | ||
| A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection | Q35702513 | ||
| A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection | Q35826494 | ||
| The poliovirus 135S particle is infectious | Q35870848 | ||
| An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. | Q35948053 | ||
| Immunological evaluation and comparison of different EV71 vaccine candidates | Q36248450 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine | Q37951381 | ||
| Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial | Q38474516 | ||
| Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. | Q39255114 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e2538 | |
| P577 | publication date | 2013-11-07 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine | |
| P478 | volume | 7 |
| Q92968336 | An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages |
| Q37130763 | Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial |
| Q38195326 | Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials |
| Q30383172 | EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). |
| Q28606867 | Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice |
| Q37628730 | Epidemiologic Features of Enterovirus 71-Associated Hand-Foot-and-Mouth Disease from 2009 to 2013 in Zhejiang, China |
| Q38835845 | Epidemiological features and spatio-temporal clusters of hand-foot-mouth disease at town level in Fuyang, Anhui Province, China (2008-2013). |
| Q30249022 | Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. |
| Q40855930 | Status of research and development of vaccines for enterovirus 71. |
| Q42230193 | Surveillance of hand, foot, and mouth disease for a vaccine |
Search more.